Literature DB >> 22079173

Clinical protection, sub-clinical infection and persistence following vaccination with extinction payloads of O1 Manisa Foot-and-Mouth Disease monovalent vaccine and challenge in goats and comparison with sheep.

M Madhanmohan1, S B Nagendrakumar, R Kumar, J Anilkumar, K Manikumar, S Yuvaraj, V A Srinivasan.   

Abstract

Small ruminants play an important role in the epidemiology of Foot-and-Mouth Disease (FMD). Small ruminants are vaccinated with one-half or one-third of cattle dose of oil-based or aqueous vaccines respectively. The extinction antigen payload in vaccine for protection in small ruminants is poorly studied. FMD seronegative Nellore sheep (n=30) and Osmanabadi goats (n=30) were vaccinated with different payloads of O(1) Manisa vaccine (0.45-5 μg). Vaccinated and sero-negative unvaccinated sheep (n=6) and goats (n=6) were challenged intradermally into the coronary band with O(1) Manisa virus. The sheep and goats were monitored for signs of FMD and samples were collected for measuring viraemia and virus associated with nasal swabs and probang samples. Clotted blood was collected for serology. Vaccines containing antigen payload up to 0.94 μg protected sheep and goats against challenge. Sheep and goats vaccinated with 0.45 μg antigen payload were poorly protected against challenge. An antigen payload of 0.94 μg was sufficient to offer complete protection and also absence of carrier status. Sheep and goats with no vaccination or with poor sero conversion to vaccination showed sub-clinical infection and became carriers. The results of the study suggest that vaccination offers protection from clinical disease even at a low payload of 0.94 μg and hence one-half of cattle dose of the oil-based vaccine formulations is sufficient to induce protective immune response in sheep and goats. Since no live virus could be isolated after 5 days post challenge from the nasal swab or probang samples even though viral RNA was detected, the risk of these animals transmitting disease was probably very low.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079173     DOI: 10.1016/j.rvsc.2011.10.006

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  6 in total

1.  Estimation of the Infection Window for the 2010/2011 Korean Foot-and-Mouth Disease Outbreak.

Authors:  Hachung Yoon; Soon-Seek Yoon; Han Kim; Youn-Ju Kim; Byounghan Kim; Sung-Hwan Wee
Journal:  Osong Public Health Res Perspect       Date:  2013-05-15

2.  The protective capacity of high payload FMDV A22 IRQ vaccine in sheep against direct-contact challenge with a heterologous, contemporary FMDV A strain from South East Asia.

Authors:  Jacquelyn Horsington; Charles Nfon; Hilary Bittner; Peter A Durr; Nagendrakumar Singanallur; Soren Alexandersen; Wilna Vosloo
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

3.  Requirements for improved vaccines against foot-and-mouth disease epidemics.

Authors:  Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

4.  Control of foot-and-mouth disease during 2010-2011 epidemic, South Korea.

Authors:  Jong-Hyeon Park; Kwang-Nyeong Lee; Young-Joon Ko; Su-Mi Kim; Hyang-Sim Lee; Yeun-Kyung Shin; Hyun-Joo Sohn; Jee-Yong Park; Jung-Yong Yeh; Yoon-Hee Lee; Min-Jeong Kim; Yi-Seok Joo; Hachung Yoon; Soon-Seek Yoon; In-Soo Cho; Byounghan Kim
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883

5.  Rapid Engineering of Foot-and-Mouth Disease Vaccine and Challenge Viruses.

Authors:  Seo-Yong Lee; Yeo-Joo Lee; Rae-Hyung Kim; Jeong-Nam Park; Min-Eun Park; Mi-Kyeong Ko; Joo-Hyung Choi; Jia-Qi Chu; Kwang-Nyeong Lee; Su-Mi Kim; Dongseob Tark; Hyang-Sim Lee; Young-Joon Ko; Min-Goo Seo; Jung-Won Park; Byounghan Kim; Myoung-Heon Lee; Jong-Soo Lee; Jong-Hyeon Park
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Virulence beneath the fleece; a tale of foot-and-mouth disease virus pathogenesis in sheep.

Authors:  Carolina Stenfeldt; Juan M Pacheco; Nagendrakumar B Singanallur; Wilna Vosloo; Luis L Rodriguez; Jonathan Arzt
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.